Systematic Reviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2022; 10(14): 4480-4493
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4480
Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020
Jia Yang, Hui-Xin Liu, Ying-Ying Su, Zhi-Sheng Liang, Hui-Ying Rao
Jia Yang, Hui-Ying Rao, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People’s Hospital, Beijing 100044, China
Hui-Xin Liu, Department of Clinical Epidemiology and Biostatistics, Peking University People’s Hospital, Beijing 100044, China
Ying-Ying Su, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361000, Fujian Province, China
Zhi-Sheng Liang, Department of Global Health, School of Public Health, Peking University, Beijing 100044, China
Author contributions: Yang J performed the research, analyzed the data, drew some of the figures and wrote the paper; Liu HX and Su YY designed the research; Liang ZS drew some of the pictures; Rao HY and Liu HX supervised the whole research, such as the design of the methodology, validation, review and editing of the paper.
Conflict-of-interest statement: All of the authors declare no conflicts of interest regarding the work in this paper. The authors declare no study sponsor involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui-Ying Rao, MD, PhD, Chief Doctor, Professor, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China. rao.huiying@163.com
Received: November 8, 2021
Peer-review started: November 8, 2021
First decision: February 14, 2022
Revised: February 28, 2022
Accepted: March 25, 2022
Article in press: March 25, 2022
Published online: May 16, 2022
Core Tip

Core Tip: This article comprehensively included the literature published in recent years and reflects a picture of the genotype constitution of hepatitis C virus (HCV), showing increases in genotype 3 and genotype 6 owing to an increase in intravenous drug users, providing the prevention direction for future HCV control.